Assessment of the quality of commercially available artemether-lumefantrine antimalarial tablets in the city of Yaoundé, Cameroon
Sahelian Journal of Responsible One Health · 07.10.2026 · 2 (3)
DOI: 10.4081/sjroh.646 ↗Kurz gefasst
Fachartikel in der Zeitschrift Sahelian Journal of Responsible One Health, online erschienen am 07.10.2026. Verfasst von Thierry Malex Nwafo Ndjimafo und 8 weiteren Autor:innen. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Malaria remains a major public health problem in sub-Saharan Africa. Artemether-lumefantrine (AL) combinations are the standard treatment, but their effectiveness can be compromised by the circulation of substandard medicines. The aim of this study was to assess the compliance of AL tablets marketed in Yaoundé (Cameroon) with international pharmaceutical standards. The study was conducted over 6 months at the National Laboratory for Drug Quality Control and Expertise (LANACOME) in Yaoundé. Three commercial products (Artefan® [Ajanta Pharma Ltd., Mumbai, India], Cartef® [GB Pharma Ltd., Surrey, UK], and Laritem® [Ipca Laboratories Ltd., Mumbai, India]) were analyzed. The tests performed included visual inspection, average weight, disintegration, friability, and identification of active ingredients by thin-layer chromatography (TLC). The results indicate that all samples analyzed met compliance standards for average weight, disintegration, and active-ingredient identification. Visual examinations revealed no signs of adulteration. Disintegration tests showed that all tablets disintegrated in less than 15 minutes, and friability tests were compliant, with mass losses of less than 1%. In addition, the frontal ratios (Rfs) obtained for artemether and lumefantrine were in line with international standards. The results underscore the importance of regular drug quality control to ensure efficacy and prevent the emergence of resistance. Further efforts are needed to strengthen market surveillance and ensure the availability of safe and effective malaria treatments.
Zitieren
APA
Ndjimafo, T. M. N., Ngodem, V. C. K., Tachoum, J. R. M., Sawi, P. C. M., Tchogang, K. C. F., Temateu, K. L. N., Tsoplefack, D. G., Biba, J. J., & Djoko, G. R. P. (2026). Assessment of the quality of commercially available artemether-lumefantrine antimalarial tablets in the city of Yaoundé, Cameroon. Sahelian Journal of Responsible One Health, 2(3). https://doi.org/10.4081/sjroh.646
Vancouver
Ndjimafo TMN, Ngodem VCK, Tachoum JRM, Sawi PCM, Tchogang KCF, Temateu KLN, et al. Assessment of the quality of commercially available artemether-lumefantrine antimalarial tablets in the city of Yaoundé, Cameroon. Sahelian Journal of Responsible One Health. 2026;2(3). doi:10.4081/sjroh.646
BibTeX
@article{Ndjimafo2026,
author = {Ndjimafo, Thierry Malex Nwafo and Ngodem, Verance Carline Kegha and Tachoum, Joseph Raphael Moyo and Sawi, Protais Cédric Mouenbori and Tchogang, Kelly Cynthia Fodom and Temateu, Kelie Laure Nangmo and Tsoplefack, Divine Guimazeu and Biba, Josue Jobin and Djoko, Godfroy Rostant Pokam},
title = {Assessment of the quality of commercially available artemether-lumefantrine antimalarial tablets in the city of Yaoundé, Cameroon},
journal = {Sahelian Journal of Responsible One Health},
year = {2026},
volume = {2},
number = {3},
doi = {10.4081/sjroh.646}
}
EUVIMED